Disease activity indicators
|
1st month
|
3rd month
|
6th month
|
12th month
|
---|
28TJC, median (IQR)
|
4 (1 ~ 9)***
|
2 (0 ~ 4)***
|
0 (0 ~ 4)***
|
1 (0 ~ 5)***
|
28SJC, median (IQR)
|
2 (0 ~ 4)***
|
0 (0 ~ 3)***
|
0 (0 ~ 1)***
|
0 (0 ~ 1)***
|
Pain VAS, median (IQR)
|
2.0 (1.7 ~ 4.0)***
|
2.0 (0 ~ 3.0)***
|
1.0 (0 ~ 2.8)***
|
1.0 (0 ~ 3.0)***
|
PtGA, median (IQR)
|
3.0 (3.0 ~ 5.0)***
|
3.0 (1.0 ~ 4.0)***
|
2.0 (0.3 ~ 3.0)***
|
2.0 (0 ~ 3.8)***
|
PrGA, median (IQR)
|
3.0 (2.3 ~ 4.0)***
|
2.0 (1.0 ~ 4.0)***
|
2.0 (0 ~ 3.0)***
|
2.0 (0 ~ 3.0)***
|
HAQ, median (IQR)
|
0.28 (0 ~ 0.94)***
|
0.15 (0 ~ 0.50)***
|
0 (0 ~ 0.25)***
|
0 (0 ~ 0.46)***
|
CRP, mg/dl, median (IQR)
|
0.44 (0.33 ~ 1.19)***
|
0.33 (0.30 ~ 0.95))***
|
0.34 (0.18 ~ 0.49)***
|
0.33 (0.30 ~ 0.89)***
|
Normal CRPa, %
|
54
|
59
|
77
|
70
|
ESR, mm/h, median (IQR)
|
34 (18 ~ 48)***
|
29 (16 ~ 38)***
|
21 (15 ~ 36)***
|
26 (13 ~ 42)***
|
Norma ESRb, %
|
27
|
38
|
41
|
39
|
DAS28c, median (IQR)
|
3.5 (2.6 ~ 4.4)***
|
2.7 (2.0 ~ 3.9)***
|
2.2 (1.5 ~ 3.2)***
|
2.6 (1.5 ~ 3.3)***
|
Remission, %
|
27
|
43
|
53
|
48
|
LDA, %
|
20
|
20
|
20
|
21
|
MDA, %
|
44
|
30
|
20
|
26
|
HDA, %
|
9
|
7
|
7
|
5
|
SDAId, median (IQR)
|
14.5 (7.6 ~ 24.2)***
|
8.9 (4.1 ~ 17.5)***
|
5.3 (1.0 ~ 12.0)***
|
6.4 (0.3 ~ 12.3)***
|
Remission, %
|
7
|
18
|
39
|
34
|
LDA, %
|
34
|
41
|
36
|
38
|
MDA, %
|
38
|
30
|
16
|
19
|
HDA, %
|
21
|
11
|
9
|
9
|
CDAIe, median (IQR)
|
13.7 (7.1 ~ 22.8)***
|
8.0 (4.0 ~ 15.9)***
|
4.5 (1.0 ~ 11.5)***
|
5.5 (0 ~ 11.0)***
|
Remission, %
|
7
|
18
|
39
|
38
|
LDA, %
|
34
|
45
|
36
|
36
|
MDA, %
|
34
|
26
|
16
|
16
|
HDA, %
|
25
|
11
|
9
|
11
|
Serum MMP-3, ng/ml, median (IQR)
|
112 (49 ~ 347)
|
130 (32 ~ 183)
|
74 (32 ~ 183)*
|
52 (32 ~ 116)***
|
Normal serum MMP-3f, %
|
32
|
38
|
46
|
62
|
RF, mg/ml, median (IQR)
|
119 (39 ~ 252)***
|
72 (20 ~ 169)***
|
49 (14 ~ 137)***
|
78(16 ~ 142)***
|
Anti-CCP, U/ml, median (IQR)
|
85 (11 ~ 300)**
|
53 (13 ~ 296)***
|
65 (16 ~ 297)**
|
112(14 ~ 300)*
|
-
Pain VAS pain visual analogue scale, 28TJC 28-joint tender joint count, 28SJC 28-joint swollen joint count, PtGA patient global assessment of disease activity, PrGA provider global assessment of disease activity, HAQ health assessment questionnaire, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 Disease Activity Score 28-joint assessment, SDAI simplified disease activity index, CDAI clinical disease activity index, LDA low disease activity, MDA moderate disease activity, HDA high disease activity, MMP-3 matrix metalloproteinase-3, RF rheumatoid factor, anti-CCP anti-cyclic citrullinated peptide antibody
- *P < 0.05, **P < 0.01, ***P < 0.001. Compared between each time point and baseline by Wilcoxon matched-pairs signed ranks sum test
-
anormal CRP: <0.5 mg/dl; bnormal ESR: <20 mm/h (female) or <15 mm/h (male); cDAS28-remission: <2.6; DAS28-LDA:2.6 ~ 3.2, DAS28-MDA:3.2 ~ 5.1, DAS28-HDA:>5.1; dSDAI-remission: <3.3; SDAI-LDA: 3.3 ~ 11.0, SDAI-MDA: 11.0 ~ 26.0, SDAI-HDA: >26.0; eCDAI-remission: <2.8; CDAI-LDA: 2.8 ~ 10.0, CDAI-MDA: 10.0 ~ 22.0, CDAI-HDA: >22.0; fnormal serum MMP-3: <60 ng/ml (female) or <120 ng/ml (male)